GT Biopharma Names Dr. Jeff Miller as Consulting Chief Medical Officer
December 14, 2022 07:30 ET
|
GT Biopharma, Inc.
BRISBANE, CALIFORNIA, Dec. 14, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative...
GT Biopharma Reports Third Quarter Fiscal 2022 Financial Results and Business Update
October 31, 2022 17:15 ET
|
GT Biopharma, Inc.
Announced two poster presentations at the Society for Immunotherapy of Cancer’s 37th Annual Meeting (SITC 2022)$20.8 million in cash, cash equivalents and short-term investments as of September 30,...
Un premier anticorps multispécifique engageant les cellules NK d'Innate sélectionné par Sanofi comme candidat-médicament
January 05, 2021 01:00 ET
|
INNATE PHARMA
Marseille, 05 janv. 2021 (GLOBE NEWSWIRE) -- IPH6101/SAR443579 est un anticorps multispécifique engageant les cellules NK (NKCE) via leur récepteur activateur NKp46 et utilisant le format...
Innate's first NK cell engager selected by Sanofi as drug candidate for development
January 05, 2021 01:00 ET
|
INNATE PHARMA
Marseille, Jan. 05, 2021 (GLOBE NEWSWIRE) -- IPH6101/SAR443579 is an NKp46-based NK cell engager (NKCE) that uses Innate’s proprietary multispecific antibody formatSelection of IPH6101/SAR443579...